Phase IIb dose-ranging study of MK-5442 versus placebo and active comparator in postmenopausal osteoporosis previously treated with oral bisphosphonate

Phase 2, randomised, double-blind trial of encaleret in postmenopausal osteoporosis and osteoporosis (6 arms), sponsored by Merck & Co. Primary endpoints: Percent change from baseline in areal lumbar spine bone mineral density, Percent change from baseline in total hip bone mineral density and 4 more. Started Sep 2009; status: completed.